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Methods: Participants with brain imaging at ages 69 and 73 years were identified from a previous
study. Simple manual measures and computationally automated volumetry were performed. Receiver
operating characteristics assessed the predictive ability of each method at baseline and on logit
regression analysis of two serial scans.
Results: Ten of 149 participants developed Alzheimer’s dementia and had lower baseline volumes
(3647 vs. 4194 mm3 P 5 .002), rates of volume loss (2126 vs. 236 mm3/y; P 5 .001), and rates
of loss in hippocampal fraction (28.55 vs. 22.35 x 1025/y; P 5 .001). Baseline volume with a
rate of change gave the highest area under the curve value of 0.96.
Discussion: Automated volumetry measuring hippocampal size at age 69 years and subsequent rate
of change predicts Alzheimer’s dementia development.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Hippocampal size can be assessed in a variety of ways,
with differing amounts of manual operator input and pro-
cessing time. Previously described methods include visual
assessment [1,2], linear measurements [1,3], manual
volumetry [3], automated volumetry [2], and signal intensity
based scoring [4]. We are interested in methods that could be
incorporated into routine clinical practice, including auto-
mated methods.
In 1992, Scheltens et al [1] published their semiquanti-
tative visual rating score for hippocampal atrophy. This
initial publication showed correlations between a five-uthor. Tel.: 144 1224 5 52175; Fax: 144 1224
nab@imagingsense.com
16/j.dadm.2016.11.007
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).point visual scale, linear measurements, age, and the pres-
ence or absence of Alzheimer’s dementia (AD). Over the
next 20 years, Scheltens’ score has been correlated with
neuropsychology rating scales, pathological scoring, and
future progression from mild cognitive impairment (MCI)
to clinical AD [5].
In 2007 and 2012, Adachi et al [3,6] published ratios of
hippocampal height and width to calculate a rounding
ratio (RR) in subjects with and without AD. The RR
correlated with manually outlined hippocampal volumes
(Spearman’s r 5 0.42), AD and Mini-Mental State
Examination (MMSE). Hippocampi had a reduced
width with increasing RR, changing the coronal cross
section from elongated to rounded. This measure has
received little attention in the literature and requires
validation.imer’s Association. This is an open access article under the CC BY-NC-ND
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mated brain segmentation and readily produces volume
measurements [7].
The individuals in our study are from a large, well-
characterized population-based cohort who were normal at
recruitment and followed up with two brain magnetic reso-
nance imaging (MRI) scans 4 years apart and with AD out-
comes recorded. This sample provides unique opportunities
to define imaging thresholds for the risk of developing de-
mentia in the general population, including in people who
are not yet symptomatic. In this study, wewill compare mea-
surement techniques and find if adding a second scan im-
proves our ability to predict who is developing AD. We
are using the area under the curve (AUC) of the receiver
operating characteristic (ROC) to compare the techniques
[8]. Values of AUC range from 1.00 which is a perfect test
down to 0.50 which represents no discriminating ability.
AUC values of 0.80 to 0.90 are regarded as good and 0.90
to 1.00 as excellent. We will present the risk of AD graphi-
cally as a continuum with baseline size and rate of change as
contributing factors.2. Methods
2.1. Subjects
A subset of the Aberdeen Birth Cohort 1936 (ABC36)
who had undergone two MRI scans was identified. ABC36
participants were recruited from participants of the Scottish
Mental Health Survey of 1947, which was conducted by the
Scottish Council for Research and Education (SCRE).
All participants were born in 1936, and almost all
(N 5 75,211) schoolchildren in Scotland were studied.
The SCRE allowed the University of Aberdeen to have
access to these data. A total of 2620 of the schoolchildren
had been tested in Aberdeen City. Nine hundred thirty-
four participants were found to be alive and living in
Aberdeen using the Community Health Index and other
identifiers. Six hundred sixty-four had Community Health
Index numbers and were approached via their primary
care physicians. The local Family Doctors’ Research
Committee requested that each prospective participant’s
family physician should sign a written invitation letter
and that those who were recently bereaved or those with
a life-threatening illness should be excluded. The family
doctors were asked to invite potential participants if
they were not known to have dementia and were living
independently in the community. Of 647 individuals
who were eligible, 506 agreed to take part in a follow-
up study of brain aging and health and 498 provided a
minimum data set of consent, clinical history, vital signs,
MMSE, and Raven’s Progressive Matrices. These 498 par-
ticipants were recruited between 1999 and 2003. Written
informed consent as approved by the Local Research
Ethics Committee was obtained by a trained research
nurse for assessment, follow-up, inspection of medicalrecords, and sharing of materials with noncommercial
collaborators. Participants with an MMSE of less than
24 on initial screening were excluded.
Beginning in 2004, a target number of 250 participants
were selected for an MRI study. The database was first scru-
tinized to remove those with known contraindications to
MRI and/or whowere in treatment for serious illness. Partic-
ipants were invited sequentially in the order in which they
had entered the study earlier.
Two hundred forty-nine participants agreed and were
scanned at an age of approximately 69 years. By the age
of about 73 years, there had been an attrition of 67 partici-
pants and 166 of the remainder agreed to a repeat MRI.
The details of the cohort are available from Whalley
et al [9].2.2. Imaging protocol
For consistent, directly comparable imaging acquisitions,
all participants at all time points were scanned in the same
1.5-T Genesis Signa NVi MRI scanner (General Electric,
Milwaukee, WI, USA). T1 spoiled gradient recalled
(SPGR) gradient echo imageswere acquired in the transverse
plane with a 20 or 22 ms repetition time, 6.0 ms echo time,
35 flip angle, 256 ! 224 matrix, field of view 24 !
18 cm, 1! 1mm in-plane resolution, 1.6mm slice thickness,
and no slice gap. The clinical teams involved in dementia
diagnosis did not have access to these research MRI scans.2.3. Hippocampal size measurements
Manual and automated hippocampal measurements re-
ported in this study are the mean of the left and right hippo-
campus. mm23 values are not corrected for total intracranial
volume.
2.3.1. Manual measurements
Hippocampal rounding measurements and Scheltens’
hippocampal atrophy scoring were performed by a single
trained rater with an agreed technique after an initial period
of double reading. The rater was blinded to the cognitive
function scores and dementia outcomes.
The rater manually realigned coronal oblique images
from the volumetric T1 series using a commercially avail-
able viewer. First, left-right rotational realignment was per-
formed along the head-foot axis. A sagittal plane was
positioned to demonstrate one of the hippocampi. The
sloping anteroposterior axis of the hippocampus was noted
on this sagittal image, and a coronal plane was angled
perpendicular to this. Images showing the realignment pro-
cess are available in the Supplementary Fig. 1.
For manual hippocampal rounding, the realigned coronal
plane was positioned at the body of the hippocampus in an
area without superior digitations and where hippocampal
detail was best visualized. Hippocampal width was taken
from the hippocampal sulcus medially to the temporal
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campal height was measured at w90 to this. For consis-
tency, all hippocampal height measurements included the
alveus because the alveus was inconsistently discernible as
a discrete structure. Hippocampal height measurements
included the gray matter of the subiculum. A sample of 20
double-read scans gave intra-class correlation coeffecients
(ICCs) of 0.78 for linear measurements and 0.07 for RR.
For each scan, the RR was expressed as the mean of both
sides’ heightOwidth. An example measurement is shown
in Fig. 1.
Scheltens’ hippocampal atrophy score [1] was performed
on a single, angled coronal section where the pons, trigemi-
nal nerves, and third ventricle were visible. The interob-
server variability of Scheltens’ score is known from
previous studies to have a k value of 0.44 to 0.51 [10].
2.3.2. Automated measurements
The volumetric analysis was performed using the Free-
Surfer software package (version 4.5.0) (http://surfer.nmr.
mgh.harvard.edu/). The brain imaging preprocessing steps
include motion correction, affine transformation to Talairach
image space, nonuniform intensity normalization for inten-
sity inhomogeneity correction, and removal of nonbrain tis-
sues [11–13].
The hippocampus is among a number of subcortical struc-
tures segmented to obtain their volume. The segmentation is
based on the voxel’s location in the volume, the neighboring
voxels’ tissue classes, and the intensity value in each voxel.
This automatic labeling procedure is comparable in accuracy
to manual labeling [14] assuring the quality of the procedure.
In addition, the obtained results are reliable when comparing
the current method with several different automatic segmen-
tation procedures [15]. The ICC for this method applied to
the hippocampus is known to be 0.96 to 0.98 [16].Fig. 1. Manual measurements for hippocampal rounding. (A) Amagnified imagew
and position of the zoomed area. Abbreviation: CSF, cerebrospinal fluid.The data follow the longitudinal stream processing
creating an unbiased template from both time points for
each subject and subsequently extracting the volumes from
each time point [16].
Left and right hippocampal volumes (mm3) were ex-
tracted, and the average of left and right hippocampal vol-
umes are reported in this study. Because we are comparing
rates of change, each person’s baseline hippocampal volume
served as a denominator and therefore normalization to total
intracranial volume was not required.2.4. AD follow-up
Interviews designed to meet International Classification
of Diseases 10th Revision or Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, criteria were con-
ducted by a clinical academic with research expertise in de-
mentia whenever dementia seemed likely.
The possibility of a dementia diagnosis was screened
by reviewing the following clinical resources approxi-
mately 11 years after the baseline MRI: (1) electronic
clinical records for dementia codes, (2) attendances at
Old Age Psychiatry memory clinics, and (3) clinical refer-
rals for imaging with a key word of “dementia”. Clinical
case files were examined, and the year of AD diagnosis
was recorded.
Owing to the known propensity of AD to affect the hippo-
campus early in its clinical course, patients with non-AD
were classified into the no Alzheimer’s group in this study.
It is known that other dementia types also cause hippocam-
pal atrophy; therefore, an analysis with all dementia types
combined is presented in the Supplementary Material.
Dementia ascertainment in this cohort is an ongoing pro-
cess which is updated over time. This study uses the latest
census date of September 2015.ith an outline of the CSF-soft tissue boundary traced for clarity. (B) The size
Fig. 2. Hippocampal size over time. Each thin line represents one of the 149
participants. Participants who developed AD are marked with red lines and
the other participants are marked with green lines. The time interval
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R, version 3.2.3, was used for statistical analysis, which is
documented and freely available [17]. Included add-on
packages were used as needed, such as eeptools [18] which
provided the “age_calc” function for accurately calculating
a participant’s age in fractional years. Independent-sample
t tests were used to assess significance between groups that
had progressed to Alzheimer’s versus those that did not.
ROCs were calculated with the pROC package [19]. Confi-
dence intervals were calculated with the default options in
pROC, including the DeLong [20] method with 2000 boot-
straps. General linear modeling was used to incorporate a
rate of change and interaction between sex and volume to
baseline measurements. The “predict” function estimated
values from the general linear models for ROC values and
to produce an easily usable, graphical illustration of AD risk.3. Results
3.1. Imaging measures and participant demographics
One hundred forty-nine (80 male, 69 female) partici-
pants were able to comply with imaging procedures and
had 3DT1 imaging data available at both MRI attendances.
The MRI scans were acquired between April 2004 and
December 2009.
The mean age at the first MRI scan was 68.6 years (SD
0.6 years, range 67.3–69.9 years). The second scan was per-
formed at a mean age of 72.8 years (SD 0.5 years, range
71.4–73.8 years). Graphs of the imaging measures over
time are shown in Fig. 2.
There are significant Pearson’s correlations between
Scheltens’ score and hippocampal volume (n 5 298,
r 5 20.342, P , .001 unadjusted), and Scheltens’ score
and hippocampal fraction (n 5 298, r 5 20.349, P , .001
unadjusted). RR fails to correlate significantly with hippo-
campal volume (n 5 298, r 5 0.009, P 5 .875 unadjusted)
or hippocampal fraction (n 5 298, r 5 0.034, P 5 .558 un-
adjusted).
3.1.1. Male and female differences
Unpaired t tests reveal no significant differences between
men (n 5 80) and women (n 5 69) in Scheltens’ scores or
RRs at both age points (unadjusted P values .055 to .665).
Men have larger hippocampal volumes than women at
age 69 years (4257 mm3 vs 4041 mm3, P5 .002 unadjusted)between each participant’s scans varies; therefore, the rate of change is
more appropriate for comparison than absolute differences in hippocampal
size. Thick lines are linear model trend lines, in red for the Alzheimer’s
group and green for the other participants. Top panel: Scheltens’ score;
127 participants have a score of zero at both of their scans, and therefore
most of the individual participant lines are overlapping along the zero level.
Second panel: Rounding ratio. Third panel: Hippocampal volume. Bottom
panel: Hippocampal fraction.
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adjusted).
Men have smaller hippocampal fractions than women
at age 69 years (0.265% vs 0.287% average of left
hippocampus and right hippocampus, P , .001 unad-
justed) and at age 73 years (0.252% vs 0.277%, P ,
.001 unadjusted).
The rate of change in hippocampal size does not differ
significantly between men and women for any of the mea-
surement methods.3.2. Dementia outcomes
Twelve participants were diagnosed with a dementia
syndrome from 2002 to 2011 (one Parkinson’s disease de-
mentia, one vascular dementia, one mixed dementia, and
nine AD). Of the nine diagnosed with AD, four were
male and five were female. Five participants were
diagnosed with AD between their first and second MRI
scans. Two participants were diagnosed with AD in the
year of their second MRI scan in 2008. Two participants
were diagnosed with AD after their second MRI scan.
The one female diagnosed with mixed dementia in 2006
was classified as a case because she had a mixture
of AD (the disease under investigation) and vascular
dementia.
3.3. Rates of change and AD
Participants who develop AD have significantly faster
losses of hippocampal volume and hippocampal fraction
compared with those who do not develop AD (Table 1).
The AD patients lose 3.42% (SD 1.59%) volume per year
compared with 0.85% (SD 0.85%) volume for controls.
Rates of change produce superior AUC values compared
with baseline for volume and for hippocampal fraction.Table 1
Rates of change in imaging parameters compared with the development of AD
Imaging parameter
Whole group,
n 5 149
(mean 6 SD)
No AD,
n 5 139
(mean 6 SD
Scheltens’ score at age 68.6 6 0.6 y 0.05 6 0.18 0.04 6 0.1
Scheltens’ score at age 72.8 6 0.5 y 0.11 6 0.33 0.08 6 0.2
DScheltens’ score/Dt, arbitrary units/y 0.02 6 0.07 0.010 6 0.0
Rounding ratio at age 68.6 6 0.6 y 0.66 6 0.10 0.68 6 0.1
Rounding ratio at age 72.8 6 0.5 y 0.67 6 010 0.67 6 0.1
DRounding ratio/Dt, no units/y 20.98 6 20.6!1023 20.81 6 20
Volume mm3 at age 68.6 6 0.6 y 4157 6 433 4194 6 41
Volume mm3 at age 72.8 6 0.5 y 3983 6 476 4046 6 41
DVolume/Dt, mm3/y 241.7 6 46.3 235.6 6 38
Hippocampal fraction at age 68.6 6 0.6 y 2.75 6 0.27!1023 2.77 6 0.2
Hippocampal fraction at age 72.8 6 0.5 y 2.64 6 0.31!1023 2.67 6 0.2
Hippocampal fraction/Dt, per y 22.77 6 3.41!1025 22.35 6 2.9
Abbreviations: AD, Alzheimer’s dementia; SD, standard deviation; ROC, receiver3.4. Logit regression analysis—The value of adding a rate
of change
Table 2 shows the value of adding a rate of change in the
prediction of AD according to the following standard logit
regression equation where the probability of AD is probAD
logitðprobADÞ
5log

probAD
12probAD

5Intercept1bbaseline!baseline measurement
1brate!rate of change
Combining a baseline measurement with a rate of change
improves the AUC for Scheltens’ scale from 0.64 to 0.78, for
volume from 0.82 to 0.95, and for hippocampal fraction
from 0.61 to 0.94. The significant P-values for brate indicate
that this is a statistically significant predictor in the logit
regression model. The risk of AD as predicted by baseline
volume and a rate of change is illustrated in Fig. 3.
3.5. Logit regression analysis—The value of adding sex
Because hippocampal volume and hippocampal fraction at
baseline were significantly different between men and women,
we considered the effect of an interaction term bbaseline!sex
logitðprobADÞ
5log

probAD
12probAD

5Intercept1bbaseline!baseline measurement
1brate!rate of change1bbaseline!sex
!baseline measurement!sex)
AD, n 5 10
(mean 6 SD)
Unadjusted
2-sample
t test P-value
between
AD and no-AD
groups
ROC AUC for
identifying those
with AD (95% CI)
6 0.25 6 0.35 .089 0.67 (0.51–0.83)
5 0.65 6 0.67 .023 0.76 (0.60–0.93)
57 0.092 6 0.179 .162 0.67 (0.46–0.87)
1 0.68 6 0.06 .819 0.52 (0.39–0.65)
0 0.67 6 0.11 .857 0.53 (0.32–0.74)
.0!1023 23.42 6 28.7!1023 .783 0.61 (0.42–0.80)
3 3647 6 407 .002** 0.84 (0.70–0.98)
8 3116 6 385 ,.001**** 0.95 (0.89–1.00)
.5 2126.1 6 63.8 .001** 0.90 (0.78–1.00)
7!1023 2.52 6 0.30!1023 .030* 0.73 (0.58–0.88)
9!1023 2.17 6 0.29!1023 .001** 0.89 (0.81–0.98)
5!1025 28.55 6 4.17!1025 .001** 0.91 (0.79–1.00)
operating characteristic; AUC, area under the curve; CI, confidence interval.
Table 2
Predicting AD outcome from a combination of baseline size and subsequent rate of change
Intercept bbaseline P value for bbaseline brate P value for brate ROC AUC (95% CI)
Scheltens’ scale 23.368 3.631 .003** 8.768 .004** 0.80 (0.64–0.96)
Rounding ratio 22.527 20.175 .961 26.553 .715 0.60 (0.40–0.80)
Volume mm3 16.8 20.00567 ,.001*** 20.0350 ,.001*** 0.96 (0.90–1.00)
Hippocampal fraction 7.292 24365 .005** 235770 ,.001*** 0.95 (0.91–0.99)
Abbreviations: AD, Alzheimer’s dementia; ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.
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tically significant, indicated by the P value of .07. The
improvement in AUC from 0.94 to 0.95 is minimal (Table 3).
The risk of AD modeled with the aforementioned param-
eters is illustrated graphically in the Supplementary Fig. 2.4. Discussion
At age 69 years, automated hippocampal volumetry is su-
perior to manual measures for identifying people who are
developing AD. This is shown by its ROC AUC of 0.84
(good) compared with 0.67 (poor) for Scheltens’ scale and
0.52 (fail) for RR.
The ability of a hippocampal size measurement to predict
AD is improved by combining a baseline measurement with
a rate of change. This is significant for Scheltens’ scale and
for automated volumetry. Therefore, in cases of diagnostic
uncertainty, the waiting time and expense of a second MRI
scan may add value for diagnosis.
Average hippocampal volume in mm3 combined with a
rate of change in mm3/y gives the highest ROC AUC of
0.96 (excellent). The predicted AD risk derived from these
two factors is shown graphically in Fig. 3.
RR performs poorly for predicting AD development.
This is in contrast to Scheltens’ scores which were per-
formed by the same observer, and which correlated
strongly with automated volumetry. Early disease, a
limited coronal resolution of 1.6 mm, measurement vari-
ability, and a limited number of AD outcomes in a normallyFig. 3. Risk of AD according to hippocampal volume at age 69 years and
subsequent rate of change. The values of hippocampal size are the average
of the left and the right hippocampi.aging cohort are possible explanations for RR’s poor per-
formance.
Prior studies have shown that the annual hippocampal at-
rophy rate is greater in patients with known AD compared
with healthy controls, for example, 2.7% versus 0.8% in
Hua et al [21], 5.59% versus 0.66% in Morra et al 2009
[22], 1.5% versus 0.6% in Sluimer et al [23], and 4.66%
versus 1.41% in Barnes et al [24] meta-analysis of prior
studies. Our rates of hippocampal volume loss were 3.42%
in participants who are developing AD and 0.85% in partic-
ipants who did not develop AD.
In 2007, Ridha et al [4] compared different manual mea-
sures of hippocampal atrophy in 47 patients with clinically
probable AD and in 26 controls aged approximately
65 years. Participants were scanned twice, at an interval
of 481 6 302 days (personal communication). Using
manual tracing, volume atrophy rates were higher at
4.49% per year in AD compared with 0.37% per year in
controls (P .001). Scheltens’ scores in the study by Ridha
et al deteriorated by 0.15 units/y in AD and, opposite to ex-
pected, deteriorated even more quickly in controls at 0.20
units/y although this was not significant. In our study,
Scheltens’ scores deteriorated faster in AD at 0.09
compared with 0.01 units/y.
Ridha et al [4] have also performed ROC analysis. The
AUC for volume atrophy rate was better than for Scheltens’
scale and for a novel measure of regional signal intensity.
The AUC numerical values were not reported, in contrast
to our study.
Longitudinal follow-up studies of participants without
clinical dementia are limited.
Jack et al [25] assessed 91 normal elderly subjects at
baseline and 1.4 years later, of whom two developed AD.
In contrast to our study, hippocampal annual percentage
change was not significantly associated with conversion in
the normal participants.
Henneman et al [26] studied the added value of atrophy
rates to baseline volume in identifying AD. In a group
comprising 44 participants with MCI, 26 patients with
subjective complaints, and 8 healthy volunteers, those
with low hippocampal volume at baseline and a high hip-
pocampal atrophy rate had a hazard ratio of 61.1 for devel-
oping AD. Our study confirms that adding atrophy rate to
baseline volume improves prediction, as shown by
improved ROC values, in a larger group without dementia
at baseline.
Table 3
Effect of adding the male-female difference in hippocampal size at age 69 years
Intercept bbaseline
P value
for bbaseline brate
P value
for brate
bbaseline!
sex
P value for
bbaseline!
sex
ROC AUC
(95% CI)
Volume mm3 17.0 20.00568 ,.001*** 20.0391 ,.001*** 20.000370 .248 0.95 (0.86–1.00)
Hippocampal
fraction
19.8 28795 .001** 251059 ,.001*** 21896 .007** 0.95 (0.88–1.00)
Abbreviations: ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.
NOTE. In this table, the bbaseline thi is the value for changing from female to male.
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well-characterized initially normal cohort, had longitudinal
imaging over 4 years, had clinical follow-up 11 years after
the first MRI, and directly compared manual to automated
methods of image analysis. We have used ROC to assess pre-
dictive ability and reported AUCs. We have combined the
predictive power of baseline and follow-up hippocampal
volumes and produced graphical plots to easily visualize
the risk of a person developing AD.
Our study has limitations. It may not be generalizable
outside our selected population, and therefore, the model
would benefit from validation in other cohorts. We have
used clinical diagnoses of AD rather than postmortem neuro-
pathologic diagnoses, and there is known to be a mismatch
rate between these [27]. This is a limitation of all clinical
studies that do not have postmortem pathology available.
The correlation between hippocampal size and the neuro-
pathologic severity of AD is imperfect [28,29], especially
if outlier points are included [30].
We chose the subset of participants who returned for a
second MRI scan at age 73 years, excluding those for
whom a follow-up MRI was unavailable. Many individuals
were diagnosed with AD between the first and second
MRI scans. In the clinical scenario, it would be advanta-
geous to know the rate of change in hippocampal size before
4 years have elapsed.
Our axial plane of volumetric image acquisition would
have maximized measurement uncertainty in the vertical di-
rection. More modern scanners have better spatial resolution
for volumetric images, and this would improve the quality of
multiplanar reconstructions (e.g., the ADNI criteria, which
were published after our data collection, require ,1.5 mm
slice thickness compared with our 1.6 mm [31], and direct
angled coronal acquisitions as used by Adachi et al [6] are
optimal for manual measurements). In our study, the com-
parison of different measurement methods against each
other remains valid, and the comparison of rates of change
over time using consistent image quality is valid. It remains
clear that Scheltens’ scale is superior to RR and that volu-
metric analysis is superior to manual measurements for the
detection of AD. Because volumetric series are acquired
routinely in clinical settings, it is feasible to incorporateautomated volumetry into routine clinical practice. We
envisage that with continuing increases in everyday
computing power, automated volumetry will become a use-
ful adjunct in the clinical setting.5. Conclusion
A combination of baseline hippocampal volume and sub-
sequent rate of change in hippocampal volume is a good pre-
dictor of older people who are developing AD.
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1. Systematic review: MEDLINE searches with the
terms “Alzheimer’s disease” (AD) and “hippocampal
atrophy rate” and a book chapter by Chong et al [32]
were used as start points. References of articles were
screened for other potentially relevant articles. The
majority of studies examine hippocampal volume
and incidence of dementia in samples of patients who
already have cognitive impairment. The added value
of hippocampal atrophy rate for predicting AD in
normal individuals is reported.
2. Interpretation: If one wishes to screen for people at
risk of AD using a quick, manual hippocampal mea-
surement at age 69 years, then Scheltens’ scale is use-
ful, whereas rounding ratio is not. If taking a single
measurement at age 69 years, then absolute hippo-
campal volume is best. For all measures, adding a
rate of change to the baseline measurement improves
the accuracy for detecting AD. Automated volumetry
plus a rate of change is an excellent predictor of AD,
and this is illustrated graphically.
3. Future directions: Validation of the model in other
large cohorts is required. The cost-effectiveness of
measuring hippocampal atrophy compared with
other biomarkers is needed for judging clinical value.References
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